Diabetes is prone to cause large vascular lesions, microangiopathy and other complications, which seriously affect the quality of life of patients and increase the burden
of disease.
With the continuous advancement of technology, diabetes drugs are also emerging, it is reported that in the past hundred years, the world has developed a total of about nine major types of diabetes treatment drugs, including sulfonylureas, biguanides, α-glycosidase inhibitors, insulin, thiazolidinediones (TZDs), glinides, GLP-1RA, DPP-IV.
inhibitors, SGLT-2 inhibitors
.
Among them, GLP-1RA drugs reduce the level of glycosylated hemoglobin performance is eye-catching, from the current clinical application trend, GLP-1RA drugs have become a hypoglycemic drug
with market potential in the industry.
The industry said that the emergence of such drugs is expected to revolutionize the entire antidiabetic drug market
.
It is understood that in recent years, the concept of diabetes control has been changing, and the role of GLP-1RA drugs has gradually been affirmed, and the recommended status has steadily improved
in major guidelines at home and abroad.
And in order to meet the increasingly rich clinical needs, GLP-1RA drugs continue to innovate, from animal origin to human origin, from daily preparations to weekly preparations, after several iterations, the GLP-1RA family is also increasingly prosperous
.
Ronaldisse and Nordisk broke down the barriers of injection of GLP-1RA drugs and added a new butyl - smegglutide tablets
to the GLP-1RA family.
According to the data, the smeglutide tablets not only solve the problem of gastric absorption of smeglutide molecules, but also achieve the same dose-response curve
as the semegglutide injection preparation.
Its half-life is 7 days, and it is administered orally once a day to obtain a smooth blood concentration curve
.
The drug was approved for marketing
in the United States in 2019.
This year, Eli Lilly launched the dual-target drug Tirzepatide (ticipapapate
).
Data show that the drug is a novel weekly subcutaneous injection of GLP-1RA/GIPR dual agonist, which can activate both GLP-1 and GIP receptors
.
Among them, GIP (glucose-dependent insulin secretion polypeptide) is a hormone
that may complement the action of GLP-1 receptor agonists.
Preclinical studies have shown that GIP can reduce weight by reducing food intake and increasing energy consumption, and binding to GLP-1 receptor agonists may have a greater impact on
patients' blood glucose and weight.
Analysts pointed out that GLP‐1RA drugs can not only significantly reduce blood glucose levels in patients with type 2 diabetes mellitus (T2DM), but also improve a variety of cardiovascular risk factors, and some GLP‐1RA have been shown to have a clear cardiovascular protective effect
。 Therefore, the Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2020 Edition) clearly state that patients with T2DM with atherosclerotic cardiovascular disease (ASCVD) or high risk of cardiovascular disease, regardless of whether their glycosylated hemoglobin (HbA1c) is up to standard, should be added to metformin with GLP-1RA or sodium-glucose co-transporter-2 inhibitor (SGLT-2i) with evidence of ASCVD benefit, as long as there are no contraindications
.
At present, GLP-1RA has undergone several update iterations, and more than 10 related products
have been approved and listed worldwide.
And China's pharmaceutical companies are also constantly working hard to promote the development of
GLP-1RA drugs.
For example, benaglutide, which was independently developed by Renhui Biologics, is a fully human GLP-1 receptor agonist (GLP-1RA
).
The data shows that compared with long-acting GLP-1RA, the fast-acting GLP-1RA benaglutide can effectively control postprandial blood glucose, reduce blood glucose fluctuations caused by meals, maintain HbA1c at the target level, in addition to reducing weight and body mass, improving blood lipid levels, and making patients benefit for a long time
.
GLP-1RA drugs with good hypoglycemic effect and multiple benefits are becoming more and more popular, but from the current point of view, most of China's diabetes drug market is still occupied by traditional drugs, and the GLP-1RA drug market is still very small, so the domestic GLP-1RA drug market needs to be further tapped
.
The industry said that with the gradual strengthening of clinical evidence, GLP-1RA drugs are expected to benefit more type 2 diabetes patients in China, and the market size is expected to further expand
.
Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.
